8-K/A: Scientific Industries Sells Genie Division, Boosts Cash

Scientific Industries, Inc. completed the sale of its Genie Division assets to Troemner, LLC for $9.6 million plus potential earn-outs, significantly improving its pro forma cash position and net income.

Summary

• Scientific Industries, Inc. (the Company) sold substantially all assets of its Genie Division of Benchtop Laboratory Equipment, including the Genie product line, fixed assets, inventory, and intellectual property, to Troemner, LLC.
• The purchase price was $9,600,000, subject to working capital adjustments, plus an earn-out of up to $1,500,000.
• Of the earn-out, $1,140,000 is contingent upon the Company's performance of supply and transition services under separate agreements.
• The Company will supply Genie products to the Purchaser for an initial period of at least six months, renewable for 3-month periods up to a maximum of twelve months, and provide transition services including training and know-how transfer.
• The Company will continue to operate its Torbal Division of Benchtop Laboratory Equipment Operations.
• Pro forma financials show a significant increase in cash and cash equivalents by $7,614,200, leading to a pro forma balance of $8,505,600 as of June 30, 2025.
• A gain on the transaction of $5,263,400 was recognized.
• For the six months ended June 30, 2025, pro forma net income was $1,440,100, a substantial improvement from the historical net loss of $(3,302,200).
• Pro forma basic and diluted earnings per common share for the six months ended June 30, 2025, improved to $0.13 from a historical loss of $(0.30).
• Pro forma revenues for the six months ended June 30, 2025, decreased by $2,727,800 to $2,008,600 due to the divestiture of the Genie product line.
• Pro forma net loss for the fiscal year ended December 31, 2024, improved to $(2,370,400) from a historical net loss of $(6,445,400).

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant cash injection, the substantial gain on the sale of the Genie Division, and the resulting improvement in net income and EPS on a pro forma basis. While revenues are reduced, the financial restructuring appears beneficial for liquidity and profitability.

Positives

• The Company received upfront consideration of $7,614,200, significantly boosting its cash and cash equivalents to $8,505,600 pro forma.
• A substantial gain on the transaction of $5,263,400 was recognized.
• The transaction transformed a historical net loss of $(3,302,200) for the six months ended June 30, 2025, into a pro forma net gain of $1,440,100.
• Potential for an additional earn-out of up to $1,500,000, with $1,140,000 tied to ongoing supply and transition services.
• The Company can now focus on its remaining Torbal Division, potentially streamlining operations and resource allocation.

Negatives

• Pro forma revenues for the six months ended June 30, 2025, decreased significantly by $2,727,800 to $2,008,600 due to the divestiture of the Genie Division.
• Pro forma gross profit for the six months ended June 30, 2025, decreased by $1,277,000 to $759,500.
• Pro forma loss from operations for the six months ended June 30, 2025, worsened by $507,600 to $(3,865,100) before accounting for the gain on disposition.
• The Company's operational footprint and revenue base are now smaller, relying solely on the Torbal Division.

Risks

• The pro forma financial information is hypothetical and may not accurately reflect the Company's actual financial position or results of operations in future periods.
• The Company's future performance will be more concentrated on the Torbal Division, increasing reliance on its success.
• Realization of the full $1,500,000 earn-out is contingent on the Company's performance of supply and transition services, which may not be fully achieved.
• The Company faces risks associated with transitioning the Genie product line to the Purchaser, including potential disruptions to supply chain or customer relationships during the transition period.

Future Outlook

The Company will continue to provide supply and transition services for the Genie product line to Troemner, LLC for an initial period of at least six months, renewable up to a maximum of twelve months. This indicates a short-to-medium term revenue stream from the divested assets while the Company focuses on its remaining Torbal Division.

Industry Context

The divestiture of the Genie Division allows Scientific Industries to streamline its operations and potentially focus on its core competencies within the benchtop laboratory equipment market, specifically the Torbal Division. This move could be indicative of a broader trend among smaller players to divest non-core assets to improve financial liquidity and strategic focus in a competitive industry.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased cash, recognized gain, and improved pro forma profitability, which could lead to better financial stability and future strategic investments.
• Employees: Employees associated with the Genie Division may be impacted by the change in ownership, though the filing does not specify details.
• Customers: Customers of the Genie product line will now be served by Troemner, LLC, with Scientific Industries providing transitional support.
• Creditors: Improved cash position and reduced liabilities could enhance the Company's creditworthiness.

Next Steps

• Continue to provide supply and transition services for the Genie product line to Troemner, LLC for an initial period of at least six months, renewable up to twelve months.
• Focus on the operations and growth of the remaining Torbal Division of Benchtop Laboratory Equipment.

Key Dates

Recommendation

The divestiture of the Genie Division provides a significant cash infusion and a substantial one-time gain, improving the Company's immediate financial health and liquidity. However, it also reduces the Company's revenue base and operational scale, concentrating future performance on the remaining Torbal Division. While the cash provides flexibility, the long-term impact depends on how this capital is deployed and the growth prospects of the smaller, focused entity. A 'hold' recommendation is appropriate as investors assess the strategic direction and operational execution post-divestiture, balancing the immediate financial benefits against the reduced scale of operations.

Keywords

Asset Sale, Divestiture, Benchtop Laboratory Equipment, Genie Division, Troemner LLC, Pro Forma Financials, SEC Filing, SCND, Cash Injection, Earn-out